TVTX: Retrophin Company Cash Volume

Graphic logo of travere.com (TVTX)

Travere Therapeutics specializes in nephrology, developing Filspari to combat rare kidney pathologies under the protection of exclusive rights. This chart illustrates the cash balance presented on GURU.Markets via the 0.47 level, which captures the latest values. A strong team of scientists and close ties with patients guarantee staff loyalty, while reliable contract manufacturing capacities ensure the stable production of drugs.

Company Cash Balance: Travere Therapeutics Inc (TVTX) for 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for Retrophin (TVTX)

- current price and projected stock value:
Summary company analysis:Travere Therapeutics
Product sample of Travere Therapeutics Inc

The development of the orphan drug portfolio of Travere Therapeutics (TVTX) requires significant capital to maintain operational stability. By analyzing the company's cash position, investors assess the level of liquidity needed to cover capital expenditures and M&A to avoid business stagnation amid geopolitical risks regarding raw material supplies from Asia, thereby confirming the company's financial autonomy and long-term viability.